骨髓增殖性肿瘤急变期患者接受异基因造血细胞移植后的结局:欧洲血液与骨髓移植学会慢性恶性肿瘤工作组的一项回顾性研究
该回顾性注册研究纳入2005至2019年间接受首次异基因造血细胞移植的663例骨髓增殖性肿瘤急变期患者,中位随访62个月,估计3年总生存率为36%(95%CI 32-36)。KPS<90和移植时疾病活跃与较低总生存率相关,而较近年份移植与较高总生存率相关;在完全缓解且KPS≥90的选择性人群中,3年总生存率为60%。
要点
- 663例骨髓增殖性肿瘤急变期患者接受异基因造血细胞移植,估计3年总生存率为36%(95%CI 32-36)。
- KPS<90(HR 1.65)和移植时疾病活跃(HR 1.45)与较低总生存率相关,较近年份移植与较高总生存率相关(HR 0.96)。
- 完全缓解且KPS≥90的患者3年总生存率为60%。
核心结论
- 在该大型骨髓增殖性肿瘤急变期患者系列中,移植后约三分之一患者3年时存活。
- 较近年份移植、KPS≥90且移植时达完全缓解的患者预后更好。
研究设计与样本
- 欧洲血液与骨髓移植学会注册-based回顾性研究,纳入2005至2019年间接受首次异基因造血细胞移植的骨髓增殖性肿瘤急变期患者,共663例。
主要发现
- 中位随访62个月,估计3年总生存率为36%(95%CI 32-36)。
- KPS<90(HR 1.65,p<.001)和移植时疾病活跃(HR 1.45,p<.001)与较低总生存率相关,较近年份移植与较高总生存率相关(HR 0.96,p=.008)。
- 在选择性患者人群中,完全缓解且KPS≥90者3年总生存率为60%。
- KPS<90(HR 1.4,p=.001)和疾病活跃(HR 1.44,p=.0004)与较低无进展生存率相关,较近年份移植与较高无进展生存率相关(HR 0.96,p=.008)。
- 移植时疾病活跃(HR 1.34,p=.03)与较高累积复发率相关,较早年份移植(HR 0.96,p=.02)与较低累积复发率相关;KPS<90(HR 1.91,p<.001)、疾病活跃(HR 1.74,p=.003)和错配相关供者移植与较高非复发死亡率相关(HR 2.66,p=.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplant (allo-HCT) provides the only potential route to long-term remission in patients diagnosed with blast phase transformation of myeloproliferative neoplasm (BP-MPN). We report on a large, retrospective European Society for Blood and Marrow Transplantation registry-based study of BP-MPN patients undergoing allo-HCT. BP-MPN patients undergoing first allo-HCT between 2005 and 2019 were included. A total of 663 patients were included. With a median follow-up of 62 months, the estimated 3-year overall survival (OS) was 36% (95% confidence interval [CI], 32-36). Factors associated with lower OS were Karnofsky Performance Score (KPS) <90 (hazard ratio [HR] 1.65, p < .001) and active disease at allo-HCT (HR 1.45, p < .001), whereas patients undergoing allo-HCT more recently associated with a higher OS (HR 0.96, p = .008). In a selected patient's population, the 3-year OS of patients undergoing allo-HCT in complete response (CR) and with a KPS ≥90 was 60%. KPS < 90 (HR 1.4, p = .001) and active disease (HR 1.44, p = .0004) were associated with a lower progression-free survival (PFS). Conversely, most recent allo-HCT associated with a higher PFS (HR 0.96, p = .008). Active disease at allo-HCT (HR 1.34, p = .03) was associated with a higher cumulative incidence of relapse (RI) and allo-HCT in earlier calendar years (HR 0.96, p = .02) associated with a lower RI. Last, KPS < 90 (HR 1.91, p < .001), active disease (HR 1.74, p = .003) and allo-HCT from mismatched related donors were associated with a higher non-relapse mortality (HR 2.66, p = .003). In this large series of BP-MPN patients, about one third were alive at 3 years after transplantation. Patients undergoing allo-HCT in the more recent era, with a KPS ≥90 and in CR at transplant had a better prognosis.
引用
- Ortí G, Gras L, Zinger N, et al. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2023. PMID: 36606718. doi:10.1002/ajh.26833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。